- Home
- DINO vs EXEL Comparison
DINO vs EXEL Comparison
Compare DINO & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DINO | EXEL |
|---|---|---|
| Founded | 1947 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 11.4B |
| IPO Year | 2022 | 2000 |
Fundamental Metrics
Financial Performance| Metric | DINO | EXEL |
|---|---|---|
| Price | $72.30 | $54.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 21 |
| Target Price | ★ $61.50 | $46.50 |
| AVG Volume (30 Days) | 2.2M | ★ 2.4M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | ★ 238.46 | 57.95 |
| EPS | ★ 3.56 | 0.79 |
| Revenue | N/A | ★ $452,477,000.00 |
| Revenue This Year | $8.01 | $13.61 |
| Revenue Next Year | N/A | $13.13 |
| P/E Ratio | ★ $19.59 | $68.89 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.16 | $33.76 |
| 52 Week High | $74.73 | $55.91 |
Technical Indicators
Market Signals| Indicator | DINO | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 59.80 | 61.36 |
| Support Level | $65.04 | $40.17 |
| Resistance Level | $73.91 | N/A |
| Average True Range (ATR) | 2.22 | 1.52 |
| MACD | 0.33 | 0.03 |
| Stochastic Oscillator | 96.37 | 64.71 |
Price Performance
Historical ComparisonAbout DINO HF Sinclair Corporation
HF Sinclair is an integrated petroleum refiner that owns and operates seven refineries serving the Rockies, midcontinent, Southwest, and Pacific Northwest, with a total crude oil throughput capacity of 678,000 barrels per day. It can produce 380 million gallons of renewable diesel annually. It holds a marketing business with over 350 distributors and 1,700 wholesale branded sites across 30 states. It also owns and operates 4,500 miles of petroleum product pipelines and terminals principally in the southwestern United States.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.